Andrews MC, Chen WS, Spencer C, et al. Molecular, immune and microbial predictors of response and toxicity to combination immune-checkpoint blockade (CICB) in melanoma (MEL) patients. SMR 2017, abstract SMR02-3.
BO-112 plus pembrolizumab bij anti-PD-1-resistent gevorderd melanoom
aug 2025 | Dermato-oncologie, Immuuntherapie